Supplementary Figure S7 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

This is a Phase 2 study (also classified as: RCT).

Key Points

Immune-related adverse events were observed in participants receiving durvalumab, highlighting potential treatment impacts.
Key evidence shows a tornado plot representing the frequency and severity of these adverse events.
Phase II open-label randomized clinical trial assessed treatment combinations of durvalumab and tremelimumab in patients.
Findings suggest the need for careful monitoring of immune-related adverse events in future trials and clinical settings.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Randomized clinical trial evaluated immune-related adverse events in head and neck squamous cell carcinoma, suggesting further analysis is necessary.

Tornado plot for immune-related adverse events.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share